Lynk Pharmaceuticals announced dosing commencement, stating that the first patient was successfully dosed in its clinical program for immune and inflammatory diseases. The update is an early-stage operational milestone, with no efficacy/safety or financial impact disclosed in the provided excerpt.
Lynk Pharmaceuticals announced dosing commencement, stating that the first patient was successfully dosed in its clinical program for immune and inflammatory diseases. The update is an early-stage operational milestone, with no efficacy/safety or financial impact disclosed in the provided excerpt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
